Medical Pharmacology Question Bank
Chapter: CNS — Sedative-Hypnotic Pharmacology, Chapter 12 — Module: Module 2 — Non-Benzodiazepine Hypnotics, Melatonin Agonists & Orexin Receptor Antagonists
Tier: CC
1. Zolpidem, zaleplon, and eszopiclone are collectively referred to as "Z-drugs." Which of the following best describes the mechanism that distinguishes them from classical benzodiazepines?
ANSWER: B
Rationale:
Z-drugs (zolpidem, zaleplon, eszopiclone) bind the same benzodiazepine recognition site on GABA-A receptors (gamma-aminobutyric acid type A receptors — the primary inhibitory ligand-gated ion channel in the brain) as classical benzodiazepines, but they show preferential affinity for receptors containing the alpha-1 (α1) subunit. The α1 subunit mediates sedation, amnesia, and anticonvulsant effects; the α2 and α3 subunits mediate anxiolysis and muscle relaxation. Because Z-drugs are relatively selective for α1, they produce sedation with less anxiolytic and muscle-relaxant activity than classical benzodiazepines, which bind α1, α2, α3, and α5 subunits non-selectively.
2. A pharmacology student asks how zolpidem produces its sedative effect at the cellular level. Which of the following most accurately describes its mechanism?
ANSWER: D
Rationale:
Zolpidem, like all benzodiazepine-site ligands, acts as a positive allosteric modulator of GABA-A receptors (gamma-aminobutyric acid type A receptors). It binds the benzodiazepine modulatory site — located at the interface between α and γ subunits — and enhances the affinity of GABA for its binding site, increasing the frequency of chloride channel opening when GABA is present. The net effect is increased chloride conductance, hyperpolarization of the neuron, and reduced neuronal excitability. Option E is the critical distractor: benzodiazepine-site drugs do NOT open chloride channels directly — they require GABA to be present and simply enhance the channel's response to it. This distinction separates benzodiazepine-site modulators from barbiturates, which at high doses can directly open chloride channels independent of GABA.
3. Ramelteon is prescribed for sleep-onset insomnia. Which receptor target accounts for its hypnotic effect?
ANSWER: A
Rationale:
Ramelteon is a selective agonist at MT1 and MT2 melatonin receptors located in the suprachiasmatic nucleus (SCN) — the brain's master circadian pacemaker. MT1 receptor activation suppresses the SCN's wake-promoting neuronal firing, reducing sleep-onset latency. MT2 receptor activation facilitates circadian phase-shifting. Together, these actions mimic the endogenous signal of evening melatonin rise that prepares the brain for sleep. Critically, ramelteon does not act on GABA-A receptors, has no abuse potential, is not a controlled substance, and does not produce dependence — distinguishing it fundamentally from Z-drugs and benzodiazepines.
4. Suvorexant was the first drug in its class approved by the FDA for insomnia. Which of the following correctly identifies its drug class and primary mechanism?
ANSWER: C
Rationale:
Suvorexant is the prototypical dual orexin receptor antagonist (DORA). Orexin (also called hypocretin) is a neuropeptide produced in the lateral hypothalamus that promotes and stabilizes wakefulness by activating OX1 and OX2 receptors throughout arousal centers in the brain. Suvorexant competitively blocks both OX1 and OX2 receptors, removing orexin-mediated wake drive and allowing the brain's natural sleep mechanisms to take over. The key conceptual distinction is that DORAs do not impose sedation — they remove a wakefulness signal. Lemborexant is the second FDA-approved DORA in this class.
5. A patient with sleep-onset insomnia wakes at 3 AM and asks whether she can take a sleep aid at that hour without feeling groggy in the morning. Which Z-drug has the pharmacokinetic profile best suited to middle-of-the-night dosing?
ANSWER: E
Rationale:
Zaleplon has a half-life of approximately one hour — the shortest of all Z-drugs — which means it undergoes near-complete elimination within 3–4 hours of dosing. A patient who takes zaleplon at 3 AM and wakes at 7 AM will have had approximately four half-lives of elimination, leaving minimal residual drug. This makes zaleplon uniquely suited to middle-of-the-night dosing when at least 4 hours of remaining sleep time are available. Its brief duration also means it has essentially no effect on sleep maintenance — it is useful only for sleep-onset difficulty, not for maintaining sleep throughout the night. Option A is the opposite of correct: eszopiclone has the longest half-life among Z-drugs (~6 hours) and is specifically avoided for middle-of-the-night use due to next-morning impairment risk. Option B and C are incorrect — zolpidem immediate-release has a half-life of approximately 2–3 hours, and the extended-release formulation has an even longer effective duration; both carry higher next-morning impairment risk than zaleplon.
6. A resident is about to prescribe zolpidem for a patient with insomnia. Which of the following correctly describes the controlled substance status of Z-drugs and orexin receptor antagonists in the United States?
ANSWER: B
Rationale:
All three Z-drugs (zolpidem, zaleplon, eszopiclone) and both approved orexin receptor antagonists (suvorexant and lemborexant) are classified as Schedule IV controlled substances under the US Controlled Substances Act. Schedule IV indicates an accepted medical use with low but recognized abuse and dependence potential. In most US states, prescribers are required to review the Prescription Drug Monitoring Program (PDMP) database before prescribing any Schedule IV substance, to identify patterns of controlled substance misuse or diversion. This shared scheduling status has important prescribing implications. By contrast, ramelteon and tasimelteon (melatonin receptor agonists) are not scheduled — a clinically significant advantage in patients with substance use history or in prescribing environments where controlled substance documentation is burdensome. Options A, C, D, and E all contain incorrect scheduling assignments for one or both drug classes.
7. A patient with a history of alcohol use disorder requires pharmacological treatment for chronic sleep-onset insomnia. Which of the following hypnotic agents has no scheduled controlled substance status and no recognized dependence liability?
ANSWER: D
Rationale:
Ramelteon is the only hypnotic agent in this list that is not a controlled substance and has no recognized dependence liability or abuse potential. Its mechanism — agonism at MT1/MT2 melatonin receptors in the suprachiasmatic nucleus (SCN) — does not involve GABA-A receptor modulation, dopaminergic reward pathways, or any mechanism associated with addiction or physical dependence. It requires no Prescription Drug Monitoring Program (PDMP) review, has no withdrawal syndrome on discontinuation, and is not subject to controlled substance prescribing regulations. These properties make it a rational first-choice pharmacological option when a hypnotic is needed in patients with current or historical substance use disorders. Options A, B, and E are all Schedule IV Z-drugs with recognized, though low, dependence potential.
8. In 2013, the FDA issued a drug safety communication requiring lower recommended doses for zolpidem. What was the primary safety concern that prompted this action?
ANSWER: A
Rationale:
The FDA's 2013 drug safety communication on zolpidem was specifically prompted by data showing that morning-after blood levels of zolpidem were high enough to impair driving performance, reaction time, and cognitive function in a substantial proportion of users — particularly women. Women eliminate zolpidem approximately 40–50% more slowly than men, resulting in higher residual blood levels at typical wake times. As a result, the FDA required that recommended doses for women be lowered: from 10 mg to 5 mg for immediate-release zolpidem, and from 12.5 mg to 6.25 mg for extended-release zolpidem. The recommended doses for men were also revised downward for the extended-release formulation. This was a landmark FDA safety action specifically addressing sex-based pharmacokinetic differences and next-morning driving impairment — a real-world functional safety outcome.
9. Among the three Z-drugs, which agent has the longest half-life and is therefore most appropriate for patients with sleep-maintenance insomnia (difficulty staying asleep)?
ANSWER: C
Rationale:
Eszopiclone (the S-enantiomer of zopiclone) has a half-life of approximately 6 hours — the longest among the three Z-drugs — which provides coverage across the full sleep period and makes it the Z-drug best suited for sleep-maintenance insomnia (waking too early or repeatedly during the night). Its longer duration does, however, increase the risk of next-morning residual sedation and impairment. Zaleplon's half-life of approximately 1 hour limits its usefulness to sleep-onset only. Zolpidem immediate-release has a half-life of approximately 2–3 hours, providing some maintenance coverage but less than eszopiclone. Option D is partially correct in that zolpidem extended-release (ER) has a biphasic release profile that extends its effective duration, but its pharmacokinetic profile does not replicate eszopiclone's true half-life.
10. Which of the following statements best explains why orexin receptor antagonists such as suvorexant are mechanistically distinct from GABA-active hypnotics such as zolpidem?
ANSWER: E
Rationale:
The fundamental mechanistic distinction between DORAs (dual orexin receptor antagonists) and GABA-active hypnotics (such as Z-drugs and benzodiazepines) lies in their direction of action. GABA-active hypnotics enhance inhibitory neurotransmission to pharmacologically impose a sedated state — the brain is being chemically pushed toward sleep regardless of its intrinsic sleep-wake status. DORAs, by contrast, block OX1 and OX2 orexin receptors, removing the wakefulness-promoting drive that orexin normally provides. Rather than pushing the brain toward sleep, DORAs simply step aside from the wake-promoting signal, allowing the brain's own sleep-regulatory machinery to function unopposed. This difference has important downstream consequences: GABA-active agents disrupt sleep architecture by suppressing slow-wave sleep (N3) and REM sleep, while DORAs preserve normal sleep stage distribution because the brain's intrinsic staging mechanisms remain intact. Options C and D contain pharmacokinetic and demographic errors not supported by evidence.
11. A clinician is counseling a patient about how Z-drugs compare to classical benzodiazepines in terms of effects on sleep quality. Which of the following correctly describes the sleep architecture advantage of Z-drugs over benzodiazepines?
ANSWER: B
Rationale:
Z-drugs, due to their relative α1 subunit selectivity, produce less suppression of slow-wave sleep (N3 — the deepest, most physically restorative stage) compared to classical benzodiazepines, which bind α1, α2, α3, and α5 subunits non-selectively and reliably suppress N3. Zolpidem immediate-release at standard doses (5–10 mg) produces minimal N3 suppression — a meaningful clinical distinction. However, this advantage is dose- and formulation-dependent: at higher doses, or with extended-release zolpidem, the α1 selectivity advantage diminishes and N3 suppression becomes more pronounced. Eszopiclone, which has less α1 selectivity than zolpidem, produces somewhat more N3 suppression than zolpidem at equivalent sedating doses. Option C is partially correct regarding REM preservation but incorrectly states that N3 suppression is equivalent to benzodiazepines.
12. Multiple polysomnographic studies have demonstrated that orexin receptor antagonists (DORAs) preserve slow-wave sleep (N3) and may modestly increase REM sleep. Which of the following best explains WHY this sleep architecture profile is mechanistically expected for this drug class?
ANSWER: D
Rationale:
The preservation of sleep architecture by DORAs follows directly and logically from their mechanism of action. Orexin (hypocretin) is a wake-promoting neuropeptide — its normal role is to stabilize wakefulness and prevent inappropriate transitions into sleep. DORAs block OX1 and OX2 orexin receptors, removing this wake-promoting signal. Because they do not pharmacologically activate any sleep-generating system, the brain is simply freed from an inhibitory constraint and allowed to sleep on its own terms. The circuits responsible for N3 generation (thalamocortical slow oscillations driven by GABAergic and other mechanisms) and REM sleep generation (pontine REM-on circuits) are entirely unaffected by DORA action — they continue to fire in their normal sequence, producing physiologically staged sleep. This contrasts sharply with GABA-active agents, which pharmacologically alter the neural substrate of sleep itself and thereby distort its architecture. Options B, C, and E describe mechanisms not associated with DORAs.
13. A patient asks why ramelteon is less effective at reducing sleep onset latency than zolpidem, even though both are prescribed for the same indication. Which of the following best explains this difference in hypnotic potency?
ANSWER: A
Rationale:
The difference in hypnotic potency between ramelteon and zolpidem reflects their fundamentally different mechanisms. Zolpidem enhances GABA-A-mediated inhibitory tone throughout the CNS — it produces direct pharmacological sedation that reduces sleep latency with a magnitude and speed that reflects this potent central action. Ramelteon acts at MT1 and MT2 melatonin receptors in the SCN (suprachiasmatic nucleus — the circadian pacemaker) to suppress wake-promoting SCN output and facilitate circadian phase-setting. This is a biological timing signal, not a sedative signal — its effect on sleep onset latency is real but modest, typically reducing sleep onset by 10–20 minutes in clinical trials compared to the larger reductions seen with GABA-active agents. The clinical implication is that ramelteon is most effective in patients whose insomnia is related to circadian misalignment or delayed sleep phase — not in patients with severe hyperarousal insomnia who need robust pharmacological sedation. Options D and E are pharmacologically incorrect.
14. The American Geriatrics Society (AGS) 2023 Beers Criteria list Z-drugs as potentially inappropriate medications in older adults. Which of the following best summarizes the primary safety concern driving this designation?
ANSWER: C
Rationale:
The AGS Beers Criteria 2023 identify Z-drugs as potentially inappropriate in older adults primarily because of their association with falls, hip fractures, motor vehicle accidents, and cognitive impairment — safety outcomes whose consequences are particularly severe in elderly patients. Older adults are more sensitive to the residual sedative and psychomotor effects of Z-drugs due to age-related changes in drug metabolism (reduced hepatic CYP activity and reduced first-pass metabolism), increased CNS sensitivity to GABAergic drugs, and reduced physiological reserve to compensate for drug-induced unsteadiness. A fall that might cause minor bruising in a younger adult can cause a hip fracture in an elderly patient with osteoporosis, with downstream morbidity and mortality that far outweighs any hypnotic benefit. The Beers Criteria recommendation is to avoid Z-drugs in older adults when possible and to use non-pharmacological approaches such as cognitive behavioral therapy for insomnia (CBT-I) as primary treatment. Options A, B, D, and E describe pharmacological concerns that are either incorrect or not the primary basis for the Beers designation.
15. A randomized clinical trial compared lemborexant to zolpidem extended-release in older adults with insomnia. Which of the following correctly summarizes the safety finding that most supports lemborexant as a preferred hypnotic in elderly patients?
ANSWER: E
Rationale:
A key randomized trial comparing lemborexant (5 mg and 10 mg) to zolpidem extended-release (6.25 mg) in older adults found that lemborexant produced superior morning-after postural stability and driving performance at both doses — a safety outcome of direct clinical relevance in elderly patients, for whom falls and motor vehicle accidents represent major morbidity risks. Sleep efficacy (total sleep time, sleep onset latency, wake after sleep onset) was comparable between the groups. This finding provides the mechanistic rationale that clinicians expect: because lemborexant acts by removing orexin wake-drive rather than enhancing GABAergic inhibition throughout the CNS, residual psychomotor and balance impairment the following morning is reduced. The 5 mg starting dose of lemborexant (with upward titration to 10 mg if needed) is the recommended approach in older adults. Options C and D are incorrect. SECTION 3 — BRIDGE QUESTIONS
16. A patient with mild obstructive sleep apnea (OSA — a disorder of repetitive upper airway collapse during sleep causing oxygen desaturation and arousal) that is well-controlled on CPAP therapy asks about adding a sleep aid for residual insomnia. Applying what you know about the mechanism of GABA-active hypnotics versus DORAs, which of the following best explains why a DORA would be mechanistically preferred over a Z-drug in this patient?
ANSWER: B
Rationale:
The theoretical concern with GABA-active hypnotics in patients with obstructive sleep apnea centers on two mechanisms: first, GABAergic potentiation reduces upper airway muscle tone (the same mechanism that produces muscle relaxation as a benzodiazepine effect), which could worsen upper airway collapsibility during sleep; second, GABA-active agents may blunt the hypoxic arousal response — the life-preserving reflex that causes patients to wake and restore airway patency when oxygen levels drop during an apnea event. DORAs act exclusively through orexin receptor blockade and do not affect GABA-A receptors, upper airway muscle tone, or hypoxic arousal circuitry through GABAergic pathways. This mechanistic difference provides the theoretical safety advantage in OSA. In patients with OSA who are adherent to CPAP (continuous positive airway pressure — a device that maintains airway patency via pressurized air), this distinction is most clinically relevant: DORAs at standard doses appear clinically reasonable when hypnotic therapy is warranted and CPAP compliance is confirmed. Option C is a pharmacokinetic distractor not relevant to OSA. Option E misrepresents the comparative pharmacokinetics.
17. A combat veteran with post-traumatic stress disorder (PTSD) presents with severe insomnia, hyperarousal, and trauma-related nightmares. Applying the sleep architecture effects of GABA-active hypnotics versus DORAs, which of the following best explains why a DORA is mechanistically preferred over a Z-drug in this patient?
ANSWER: D
Rationale:
PTSD is characterized by disrupted REM sleep, pathological hyperarousal, and trauma-related nightmares. The sleep pathophysiology of PTSD involves excessive REM fragmentation, intrusion of threat-related memory during REM sleep, and failure of the normal REM-dependent emotional processing that is believed to be important in trauma memory consolidation and eventual resolution. GABA-active hypnotics such as Z-drugs suppress REM sleep — reducing both REM duration and the intensity of dreaming. In PTSD, this REM suppression may worsen nightmare recall upon drug discontinuation (REM rebound), and there is theoretical concern that chronically suppressing REM interferes with the emotional processing of trauma memories that REM sleep appears to facilitate. DORAs, by contrast, preserve or modestly increase REM sleep while reducing orexin-mediated wake drive and hyperarousal. This pharmacological profile is mechanistically well-matched to PTSD sleep pathophysiology: reducing hyperarousal-driven wakefulness without disrupting the REM-dependent processes potentially important in trauma recovery. Option B has the mechanism backward — Z-drugs suppress, not increase, REM sleep. Option E is pharmacologically incorrect.
18. In 2019, the FDA added a boxed warning to zolpidem, zaleplon, eszopiclone, and other Schedule IV hypnotics. Which of the following correctly identifies the safety concern addressed by this warning?
ANSWER: A
Rationale:
The FDA's April 2019 boxed warning — the most prominent safety warning the FDA can require — addressed the risk of serious injuries and deaths from complex sleep behaviors associated with zolpidem, zaleplon, eszopiclone, suvorexant, and other Schedule IV hypnotic agents. Complex sleep behaviors are automatic, complex activities performed during partial arousal from sleep — sleepwalking, sleep-driving, preparing and eating food, making phone calls, and other activities — of which the patient has no memory upon waking. Cases involving motor vehicle accidents, falls, and deaths had been reported in post-marketing surveillance. The FDA warning specified that these behaviors can occur even at recommended doses, even on first use, and even without prior history. The warning required that prescribers counsel patients about this risk and that patients be instructed to discontinue the medication if a complex sleep behavior occurs. This black box warning applies to all Schedule IV hypnotics as a class. Options C, D, and E describe adverse effects not associated with this specific FDA action.
19. A 68-year-old patient has been taking zolpidem 10 mg nightly for three years. Her physician wants to discontinue it. Which of the following describes the evidence-supported approach to Z-drug deprescribing?
ANSWER: C
Rationale:
Structured deprescribing of chronic Z-drugs — particularly in elderly patients — is supported by a growing evidence base. The recommended approach involves a gradual taper, typically reducing the dose by approximately 25% every 2 weeks, combined concurrently with cognitive behavioral therapy for insomnia (CBT-I — a structured non-pharmacological intervention that addresses maladaptive sleep behaviors, hyperarousal cognitions, and sleep hygiene). Randomized trial data show that this combined approach achieves successful discontinuation in over 60% of patients, with minimal withdrawal symptoms compared to abrupt discontinuation. Patients should be counseled to expect rebound insomnia — typically 1–2 nights of worse sleep immediately after each dose reduction — which is a self-limited withdrawal phenomenon qualitatively distinct from treatment failure and not a reason to resume the prior dose. Option B unnecessarily introduces a benzodiazepine with higher dependence liability. Option D lacks evidence and substitutes one controlled substance for another.
20. Among IV sedatives used in the ICU, dexmedetomidine (an alpha-2 adrenergic agonist that inhibits locus coeruleus noradrenergic firing) produces a sedative state that most closely approximates physiological sleep. Which of the following best explains why this may contribute to lower delirium rates compared to propofol or midazolam in critically ill patients?
ANSWER: E
Rationale:
Dexmedetomidine acts by inhibiting noradrenergic neurons in the locus coeruleus (the brain's primary noradrenergic arousal nucleus), producing a state that mimics the natural loss of locus coeruleus activity that occurs during normal N2 sleep. EEG recordings during dexmedetomidine sedation show spontaneous sleep spindles and features of physiological N2 sleep, and arousal pathways remain functionally intact — patients can be woken with verbal stimulation more readily than with propofol. Propofol produces an EEG state that shares some features with N2/N3 sleep but lacks the cyclical REM-NREM architecture of natural sleep; patients sedated with propofol undergo REM deprivation during prolonged ICU sedation. Midazolam similarly suppresses REM. Since ICU delirium (an acute disorder of attention, awareness, and cognition common in critically ill patients) is strongly associated with circadian rhythm disruption and REM sleep deprivation, dexmedetomidine's architecture-preserving, more physiological sedation profile may partially explain the lower delirium rates observed in clinical trials.
21. Tasimelteon is a melatonin receptor agonist structurally related to ramelteon. Unlike ramelteon, which is approved for general sleep-onset insomnia, tasimelteon has a specific FDA-approved indication. Which of the following correctly identifies that indication?
ANSWER: B
Rationale:
Tasimelteon is FDA-approved specifically for Non-24-hour sleep-wake disorder (Non-24) — a rare but profoundly disabling circadian rhythm disorder that affects the majority of totally blind individuals. In sighted people, light enters the retina and travels via the retinohypothalamic tract to entrain the SCN's circadian clock to the 24-hour solar day. In totally blind individuals, this photic input is absent, and the SCN free-runs on its intrinsic period of approximately 24.5 hours — meaning the circadian clock drifts progressively later each day, causing the sleep period to cycle in and out of phase with the conventional 24-hour day. Tasimelteon, by acting as a potent MT1/MT2 agonist, provides a pharmacological substitute for the melatonin signal that blind individuals cannot generate in response to light, entraining the clock and stabilizing the sleep-wake cycle to the 24-hour day. This is a distinct pharmacological role from the general sleep-onset indication of ramelteon. Options A, C, and E describe circadian disorders for which tasimelteon is not specifically FDA-approved (though melatonin-based approaches are used off-label in some).
22. Quetiapine (an atypical antipsychotic) is frequently used off-label at low doses (25–100 mg at bedtime) as a hypnotic, particularly in psychiatric inpatient settings. Which of the following best describes the appropriate position of quetiapine in insomnia management?
ANSWER: D
Rationale:
Quetiapine produces sedation at low doses through potent H1 (histamine) and 5-HT2A (serotonin receptor subtype 2A) antagonism, and it is used with considerable frequency off-label as a hypnotic — particularly in psychiatric settings. However, current sleep medicine guidelines, including the American Academy of Sleep Medicine (AASM) clinical practice guidelines, do not recommend quetiapine for uncomplicated insomnia disorder. The reason is straightforward: quetiapine carries the complete adverse effect burden of atypical antipsychotics, including risk of metabolic syndrome (weight gain, hyperglycemia, dyslipidemia), tardive dyskinesia (an irreversible movement disorder with long-term use), QTc prolongation, orthostatic hypotension, and extrapyramidal effects. These risks are not acceptable when safer, evidence-based pharmacological and non-pharmacological alternatives exist for insomnia. Quetiapine use as a hypnotic is appropriate only when the patient has a concurrent psychiatric indication — such as bipolar disorder, PTSD, or treatment-resistant depression — that independently justifies the medication, and insomnia treatment becomes a secondary benefit. Option C is a false safety claim — quetiapine's lack of GABA-A activity does not establish superiority in OSA.